Michael Barbella, Managing Editor03.18.23
Talk about sweet support: MPO website visitors craved the latest and greatest in diabetes technology this past week, driving up page views for Associate Editor Sam Brusco's feature on treatment advancements for the disease. Among the innovations showcased were the much-heralded Dexcom G7 continuous glucose monitor; Tandem Diabetes t:slim X2 insulin pump; Insulet's Omnipod 5 automated insulin delivery system; and Fractyl's organ editing technology, which directly targets and modifies the duodenum and pancreas to address the causes of type 2 diabetes.
New study results and products were popular with cyber tourists, too. Grifols touted positive topline results from a phase 3b clinical trial of its plasma-protein based fibrin sealant (FS) in pediatric patients. Having met all primary and secondary endpoints, the study is expected to facilitate regulatory approval to expand the use of the FS-based biosurgery treatment, currently indicated for adults, to children and adolescents as well.
Other site traffic drivers included Medtronic's latest regulatory approval, Proximie's most recent product release, and Getinge's acquisition.
Medtronic racked up page views for the CE mark clearance of its Affera mapping and ablation system, which includes the Sphere-9 catheter and Affera Prism-1 mapping software. Together, the system creates a new electrophysiology paradigm using the Sphere-9 pulsed field ablation, radiofrequency, and high-density mapping catheter. Sphere-9 maps and ablates atrial arrhythmias and generates real-time feedback via mapping and navigation software.
Proximie attracted website visitors with the launch of its PxLens, a lightweight, wearable "smart glasses" device equipped with a 4K camera and embedded software. The head-mounted device allows surgeons to share a ‘first-person’ perspective of open surgeries and minimally invasive procedures. The PxLens features seamless integration into Proximie’s cloud-based platform for telepresence, content, and insights from the operating room.
MPO followers also favored Getinge's $16 million purchase of Ultra Clean Systems, a U.S. manufacturer of ultrasonic cleaning technologies used in hospitals and surgery centers to decontaminate surgical instruments.
New study results and products were popular with cyber tourists, too. Grifols touted positive topline results from a phase 3b clinical trial of its plasma-protein based fibrin sealant (FS) in pediatric patients. Having met all primary and secondary endpoints, the study is expected to facilitate regulatory approval to expand the use of the FS-based biosurgery treatment, currently indicated for adults, to children and adolescents as well.
Other site traffic drivers included Medtronic's latest regulatory approval, Proximie's most recent product release, and Getinge's acquisition.
Medtronic racked up page views for the CE mark clearance of its Affera mapping and ablation system, which includes the Sphere-9 catheter and Affera Prism-1 mapping software. Together, the system creates a new electrophysiology paradigm using the Sphere-9 pulsed field ablation, radiofrequency, and high-density mapping catheter. Sphere-9 maps and ablates atrial arrhythmias and generates real-time feedback via mapping and navigation software.
Proximie attracted website visitors with the launch of its PxLens, a lightweight, wearable "smart glasses" device equipped with a 4K camera and embedded software. The head-mounted device allows surgeons to share a ‘first-person’ perspective of open surgeries and minimally invasive procedures. The PxLens features seamless integration into Proximie’s cloud-based platform for telepresence, content, and insights from the operating room.
MPO followers also favored Getinge's $16 million purchase of Ultra Clean Systems, a U.S. manufacturer of ultrasonic cleaning technologies used in hospitals and surgery centers to decontaminate surgical instruments.
